Company Analysis
Sign in

Protalix BioTherapeutics, Inc. (PLX)

NYSE: PLX · Biological Products, (No Diagnostic Substances) · Hackensack, NJ · filing with the SEC since 1996
Full chart Alerts Compare
Grade5.4
◀ Past 4.9● Present 7.0▶ Future 3.8
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

25 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Protalix BioTherapeutics, Inc.’s names, not what it holds today.

Patents granted
25
25 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against none in 2024 and 1 in 2023
Applications published
48
2 of them in 2025
Names they are printed under
2
a subsidiary
By yearGrantedApplications published
'10'11'12'13'14'15'16'17'18'19'20'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals4
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Protalix Ltd. a subsidiary
IL, as the owner printed on each patent
25 granted
37 published
Protalix Ltd. a subsidiary
named as the applicant on its applications, in IL
0 granted
11 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 12, 202512,385,054Removal of constructs from transformed cellsBiotechnologyProtalix Ltd.
Aug 12, 202512,385,026Stabilized alpha-galactosidase and uses thereofPharmaceuticalsProtalix Ltd.
Jan 14, 202512,194,079Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidasePharmaceuticalsProtalix Ltd.
Nov 14, 202311,814,657Modified DNase and uses thereofPharmaceuticalsProtalix Ltd.
Jan 18, 202211,225,648Modified DNase and uses thereofPharmaceuticalsProtalix Ltd.
Dec 22, 202010,870,842Stabilized alpha-galactosidase and uses thereofPharmaceuticalsProtalix Ltd.
Aug 4, 202010,730,925Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing samePharmaceuticalsProtalix Ltd.
Jul 30, 201910,364,413Large scale disposable bioreactorBiotechnologyProtalix Ltd.
May 7, 201910,280,414Stabilized α-galactosidase and uses thereofPharmaceuticalsProtalix Ltd.
Oct 2, 201810,087,232Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapyPharmaceuticalsProtalix Ltd.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 30, 20252025/0332228METHODS OF TREATING DISEASES ASSOCIATED WITH ELEVATED URIC ACIDPharmaceuticalsProtalix Ltd.
May 1, 20252025/0134968THERAPEUTIC REGIMEN FOR THE TREATMENT OF FABRY USING STABILIZED ALPHA-GALACTOSIDASEPharmaceuticalsProtalix Ltd.
Aug 8, 20242024/0263150METHODS OF TREATING DISEASES ASSOCIATED WITH ELEVATED URIC ACIDPharmaceuticalsProtalix Ltd.
Jan 4, 20242024/0002814MODIFIED URICASE AND USES THEREOFPharmaceuticalsProtalix Ltd.
Dec 28, 20232023/0416707LONG-ACTING DNASEPharmaceuticalsProtalix Ltd.
Nov 23, 20232023/0374447DICER-LIKE KNOCK-OUT PLANT CELLSBiotechnologyProtalix Ltd.
Mar 9, 20232023/0074255STABILIZED ALPHA-GALACTOSIDASE AND USES THEREOFPharmaceuticalsProtalix Ltd. · patent 12,385,026 granted from it
Jan 26, 20232023/0022576REMOVAL OF CONSTRUCTS FROM TRANSFORMED CELLSBiotechnologyProtalix Ltd. · patent 12,385,054 granted from it
Apr 7, 20222022/0106578MODIFIED DNASE AND USES THEREOFPharmaceuticalsProtalix Ltd. · patent 11,814,657 granted from it
May 21, 20202020/0155654THERAPEUTIC REGIMEN FOR THE TREATMENT OF FABRY USING STABILIZED ALPHA-GALACTOSIDASEPharmaceuticalsProtalix Ltd. · patent 12,194,079 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton PLX · research, not advice